Tag: Prescription Drugs
Herpes Simplex Virus Type 1 May Affect Risk for Alzheimer Disease
Patients with HSV-1 who used antiherpetics were less likely to develop Alzheimer disease than those who did not
Lipoprotein(a) Levels Tied to Increased Risk of Recurrent Atherosclerotic CVD Events
Deleterious effect of lipoprotein(a) ≥180 nmol/L possibly mitigated by high-impact LDL-cholesterol-lowering therapy
Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia
Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
Methotrexate noninferior to prednisone with regard to change from baseline to week 24 in percentage of predicted forced vital capacity
Medicaid Unwinding Linked to Disruption of Chronic Medication Therapy in Youth
Pausing Medicaid eligibility determinations during COVID-19 pandemic linked to increased risk for having no prescriptions and cash-pay prescriptions
Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice
Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications
Gabapentinoids Not Directly Associated With Risk of Self-Harm
However, increased risk of self-harm is seen before initiation of treatment, during initial phase of treatment, and after discontinuation
Mortality Up With Loss of Low-Income Subsidy for Drugs
Mortality difference amplified for users of medications for cardiovascular disease, chronic lung disease, HIV
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
Risk for postoperative eKA slightly increased; lower risks seen for perioperative acute kidney injury and 30-day mortality
Ubrogepant During Prodromal Phase of Migraine Eases Symptoms
Ubrogepant may treat prodromal symptoms, including photophobia, fatigue, phonophobia, cognitive dysfunction from as early as one hour












